Literature DB >> 19479822

Reduced expression and novel splice variants of ING4 in human gastric adenocarcinoma.

Ming Li1, Yan Jin, Wen-jing Sun, Yang Yu, Jing Bai, Dan-dan Tong, Ji-ping Qi, Jin-rong Du, Jing-shu Geng, Qi Huang, Xiao-yi Huang, Yun Huang, Fei-fei Han, Xiang-ning Meng, Jesusa L Rosales, Ki-Young Lee, Song-bin Fu.   

Abstract

ING4, a new member of the ING (inhibitor of growth) family of tumour suppressor genes, has been found to be deleted or down-regulated in gliomas, breast tumours, and head and neck squamous cell carcinomas. The goal of the present study was to investigate whether the expression and alternative splicing of ING4 transcripts are involved in the initiation and progression of stomach adenocarcinoma. ING4 mRNA and protein expression was examined in gastric adenocarcinoma tissues and human gastric adenocarcinoma cell lines by RT-PCR, real-time RT-PCR, tissue microarray immunohistochemistry, and western blot analysis. Alterations in ING4 transcripts were determined through sequence analysis of ING4 cDNA. Our data showed that ING4 mRNA and protein were dramatically reduced in stomach adenocarcinoma cell lines and tissues, and significantly less in female than in male patients. We also found that reduced ING4 mRNA expression correlated with the stage of the tumour. Interestingly, by sequence analysis, we discovered five novel aberrantly spliced variant forms of ING4_v1 and ING4_v2. These variants cause a codon frame-shift and, eventually, deletion of the NLS or PHD domain contributing to the mislocalization of p53 and/or HAT/HDAC complexes and, subsequently, altered gene expression in gastric adenocarcinoma. These results suggest that attenuated and aberrant ING4 expression may be involved in the initiation and progression of stomach adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19479822      PMCID: PMC3855470          DOI: 10.1002/path.2571

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  19 in total

1.  Novel splice variants of ING4 and their possible roles in the regulation of cell growth and motility.

Authors:  Motoko Unoki; Jiang Cheng Shen; Zhi-Ming Zheng; Curtis C Harris
Journal:  J Biol Chem       Date:  2006-09-13       Impact factor: 5.157

2.  Expression of estrogen receptor-alpha and -beta mRNAs in human gastric cancer.

Authors:  Naofumi Takano; Norio Iizuka; Shoichi Hazama; Shigefumi Yoshino; Akira Tangoku; Masaaki Oka
Journal:  Cancer Lett       Date:  2002-02-25       Impact factor: 8.679

3.  Estrogen and risk of gastric cancer: a protective effect in a nationwide cohort study of patients with prostate cancer in Sweden.

Authors:  Mats Lindblad; Weimin Ye; Carlos Rubio; Jesper Lagergren
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-12       Impact factor: 4.254

Review 4.  Gastric cancer: global pattern of the disease and an overview of environmental risk factors.

Authors:  D Forman; V J Burley
Journal:  Best Pract Res Clin Gastroenterol       Date:  2006       Impact factor: 3.043

5.  Pattern and Time Trends of Stomach Cancer in Asia from 1950-99.

Authors:  Le Tran Ngoan; Takesumi Yoshimura
Journal:  Asian Pac J Cancer Prev       Date:  2002

6.  Apoptotic pathway induced by transduction of RUNX3 in the human gastric carcinoma cell line MKN-1.

Authors:  Yumi Nagahama; Mika Ishimaru; Mitsuhiko Osaki; Toshiaki Inoue; Akihiro Maeda; Chisato Nakada; Masatsugu Moriyama; Kenzo Sato; Mitsuo Oshimura; Hisao Ito
Journal:  Cancer Sci       Date:  2007-10-22       Impact factor: 6.716

7.  Gastric parietal cells: potent endocrine role in secreting estrogen as a possible regulator of gastro-hepatic axis.

Authors:  Takashi Ueyama; Nobuyuki Shirasawa; Mitsuteru Numazawa; Keiko Yamada; Momoko Shelangouski; Takao Ito; Yoshihiro Tsuruo
Journal:  Endocrinology       Date:  2002-08       Impact factor: 4.736

8.  p33(ING1b) stimulates the transcriptional activity of the estrogen receptor alpha via its activation function (AF) 2 domain.

Authors:  Tatsuya Toyama; Hirotaka Iwase; Hiroko Yamashita; Yasuo Hara; Hiroshi Sugiura; Zhenhuan Zhang; Ichiro Fukai; Yutaka Miura; Karl Riabowol; Yoshitaka Fujii
Journal:  J Steroid Biochem Mol Biol       Date:  2003-10       Impact factor: 4.292

9.  p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity.

Authors:  Masayuki Shiseki; Makoto Nagashima; Remy M Pedeux; Mariko Kitahama-Shiseki; Koh Miura; Shu Okamura; Hitoshi Onogi; Yuichiro Higashimoto; Ettore Appella; Jun Yokota; Curtis C Harris
Journal:  Cancer Res       Date:  2003-05-15       Impact factor: 12.701

Review 10.  Grow-ING, Age-ING and Die-ING: ING proteins link cancer, senescence and apoptosis.

Authors:  Michael Russell; Philip Berardi; Wei Gong; Karl Riabowol
Journal:  Exp Cell Res       Date:  2006-03-03       Impact factor: 3.905

View more
  20 in total

1.  A dominant mutant allele of the ING4 tumor suppressor found in human cancer cells exacerbates MYC-initiated mouse mammary tumorigenesis.

Authors:  Suwon Kim; Alana L Welm; J Michael Bishop
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

2.  Deletion of the inhibitor of growth 4 (ING4) tumor suppressor gene is prevalent in human epidermal growth factor 2 (HER2)-positive breast cancer.

Authors:  Coya Tapia; Inti Zlobec; Sandra Schneider; Ergin Kilic; Uwe Güth; Lukas Bubendorf; Suwon Kim
Journal:  Hum Pathol       Date:  2011-02-11       Impact factor: 3.466

3.  ING4 is negatively correlated with microvessel density in colon cancer.

Authors:  Chun Lou; Shixiong Jiang; Xinggang Guo; Xin-shu Dong
Journal:  Tumour Biol       Date:  2012-09-28

4.  Tumor suppressor ING4 overexpression contributes to proliferation and invasion inhibition in gastric carcinoma by suppressing the NF-κB signaling pathway.

Authors:  Shijie Li; Tianli Fan; Hongtao Liu; Jiangtao Chen; Changjiang Qin; Xuequn Ren
Journal:  Mol Biol Rep       Date:  2013-09-22       Impact factor: 2.316

5.  Association between the expression of inhibitor of growth family member 4 and the progression of clear cell renal carcinoma.

Authors:  Yuxin Ren; Song Zhao; He Chen; Ying-Mei Fu; Bai Zhao
Journal:  Oncol Lett       Date:  2017-06-21       Impact factor: 2.967

6.  Recombinant ING4 suppresses the migration of SW579 thyroid cancer cells via epithelial to mesenchymal transition.

Authors:  Chuan-Jiang Wang; Dong Yang; Ying-Wei Luo
Journal:  Exp Ther Med       Date:  2015-05-22       Impact factor: 2.447

7.  Citrullination of inhibitor of growth 4 (ING4) by peptidylarginine deminase 4 (PAD4) disrupts the interaction between ING4 and p53.

Authors:  Qin Guo; Walter Fast
Journal:  J Biol Chem       Date:  2011-03-22       Impact factor: 5.157

Review 8.  Inhibitor of growth tumor suppressors in cancer progression.

Authors:  Brad Piche; Gang Li
Journal:  Cell Mol Life Sci       Date:  2010-03-02       Impact factor: 9.261

9.  Expression of tumor suppressor gene ING4 in ovarian carcinoma is correlated with microvessel density.

Authors:  Yinglan Liu; Liqian Yu; Yingwei Wang; Yaling Zhang; Yingchao Wang; Guangmei Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2012-01-08       Impact factor: 4.553

10.  Reduced expression and prognostic implication of inhibitor of growth 4 in human osteosarcoma.

Authors:  Dahang Zhao; Xiangjie Liu; Yunge Zhang; Zhaoming Ding; Feng Dong; Hongwei Xu; Baoxin Wang; Wenbo Wang
Journal:  Oncol Lett       Date:  2016-03-09       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.